DIAGNOSIS AND TREATMENT OF MF AND PV: Where Are We and Where Are We Going?
December 23, 2021
December 23, 2022
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Physicians’ Education Resource®, LLC.
This activity is supported by educational grants from AbbVie, Inc.; Bristol Myers Squibb; Constellation Pharmaceuticals; Geron Corporation; Incyte Corporation; PharmaEssentia USA; Protagonist Therapeutics, Inc.; Sierra Oncology, Inc.; and Sumitomo Dainippon Pharma Oncology, Inc.
- Physicians — maximum of 3.0 AMA PRA Category 1 Credit(s)™
- Nurses — 3.0 Contact Hours
All other health care professionals completing this course will be issued a statement of participation.
This educational program is directed toward medical oncologists, hematologists, and other health care professionals who treat patients with MPNs. Fellows, researchers, nurse practitioners, nurses, physician assistants, and other allied professionals interested in hematologic malignancies are also invited to attend.
Myeloproliferative neoplasms (MPNs) comprise a diverse range of hematologic cancers, with optimal management requiring careful risk stratification and treatment planning. In recent years, refinements in disease biology and development of novel therapeutic options have led to improved control of symptoms and lessened risk of serious adverse events.
This virtual, on-demand webcast is specifically designed to meet the needs of busy clinicians who treat patients who have received a diagnosis of polycythemia vera (PV) or myelofibrosis (MF) by providing an update on optimal diagnosis, treatment selection, and emerging therapeutic options. These didactic presentations are placed into real-world context through discussion of 5 case scenarios spanning the disease continuum for PV and MF. These cases will help place recent findings and treatment recommendations into context for participants.
This educational activity is an archive of the virtual symposium held on December 10, 2021.
Upon completion of this activity, you should be better able to:
- Determine the impact of genetics, symptom burden, and risk stratification on therapy selection in MPNs
- Evaluate the clinical profiles of current and emerging therapeutic strategies in MPNs across lines of therapy
- Identify and manage disease-associated symptoms and treatment-related toxicities in patients with MPNs
- Translate updated clinical trial evidence and guidelines into personalized treatment plans for patients with MPNs to optimize care across the disease continuum
Srdan Verstovsek, MD, PhD
United Energy Resources, Inc. Professor of Medicine
Director, Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Andrew Kuykendall, MD
Department of Malignant Hematology
Moffitt Cancer Center
Lindsey Lyle, MS, PA-C
Assistant Professor, Medicine-Hematology
University of Colorado Anschutz Medical Campus
UCHealth Blood Disorders and Cell Therapies Center
Laura Michaelis, MD
Interim Chief, Division of Hematology and Oncology
Medical College of Wisconsin
Cancer Center, Froedtert Hospital
Abdulraheem Yacoub, MD
Associate Professor of Medicine
University of Kansas Medical Center
Clinical Director of Ambulatory Hematology Clinics
The University of Kansas Cancer Center
Kansas City, KS
Physician Accreditation Statement
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 3.0 Contact Hours.
Disclosures of Conflicts of Interest
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.
- Srdan Verstovsek, MD, PhD
- Grant/Research Support: Incyte Corporation; Roche; NS Pharma, Inc.; Celgene Corporation; Gilead Sciences, Inc.; Promedior, Inc.; CTI BioPharma Corp.; Genentech, Inc.; Blueprint Medicines; Novartis; Sierra Oncology, Inc.; PharmaEssentia; AstraZeneca; Italfarmaco; Protagonist Therapeutics, Inc.
- Consultant: Constellation Pharmaceuticals; Sierra Oncology, Inc.; Incyte Corporation; Novartis; Celgene Corporation; Bristol Myers Squibb.
- Andrew Kuykendall, MD
- Grant/Research Support: Protagonist Therapeutics, Inc.; Sierra Oncology, Inc.; Prelude Therapeutics; Blueprint Medicines.
- Consultant: : Protagonist Therapeutics, Inc.; PharmaEssentia; Blueprint Medicines; Incyte Corporation; CTI BioPharma Corp.; Constellation Pharmaceuticals.
- Lindsey Lyle, MS, PA-C
- Advisory Boards: Bristol Myers Squibb and Protagonist Therapeutics.
Laura Michaelis, MD has no relevant financial relationships with ineligible companies.
- Abdulraheem Yacoub, MD
- Speakers’ Bureau: Incyte Corporation; Agios Pharmaceuticals Inc.; Novartis.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Instructions for Participation and Credit
- Complete the activity (including pre- and post-activity assessments).
- Answer the evaluation questions.
- 3Request credit using the drop-down menu.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.